Identification

Name
Nebivolol
Accession Number
DB04861
Type
Small Molecule
Groups
Approved, Investigational
Description

Nebivolol is a highly cardioselective vasodilatory beta1 receptor blocker used in treatment of hypertension. In most countries, this medication is available only by prescription. [Wikipedia]

Structure
Thumb
Synonyms
  • 1,1'-[Bis(6-fluoro-3,4-dihydro-2H-1-benzopyran-2-yl)]-2,2'-iminodiethanol
  • 1,1'-Bis(6-fluoro-3,4-dihydro-2H-1-benzopyran-2-yl)-2,2'-iminodiethanol
  • alpha,alpha'-(iminobismethylene)bis-(6-fluoro-3,4-dihydro-2H-1-benzopyran-2-methanol)
  • alpha,alpha'-(iminodimethylene)bis-(6-fluoro-2-chromanmethanol)
  • Narbivolol
  • Nebivololum
External IDs
PI-21858 / R65,824
Product Ingredients
IngredientUNIICASInChI Key
Nebivolol hydrochlorideJGS34J7L9I152520-56-4JWEXHQAEWHKGCW-VCVZPGOSSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
BystolicTablet5 mg/1OralPhysicians Total Care, Inc.2008-10-02Not applicableUs00456 1405 01 nlmimage10 683a3461
BystolicTablet20.0 mgOralForest Laboratories2013-04-02Not applicableCanada
BystolicTablet10 mg/1OralA S Medication Solutions2008-01-222017-06-20Us
BystolicTablet10.0 mgOralForest Laboratories2013-04-02Not applicableCanada
BystolicTablet10 mg/1OralCarilion Materials Management2008-01-22Not applicableUs
BystolicTablet5 mg/1OralAllergan2008-01-22Not applicableUs
BystolicTablet5 mg/1OralCardinal Health2008-01-22Not applicableUs
BystolicTablet5 mg/1OralA S Medication Solutions2008-01-22Not applicableUs
BystolicTablet20 mg/1OralAllergan2008-01-22Not applicableUs
BystolicTablet10 mg/1OralCardinal Health2008-01-22Not applicableUs00456 1410 01 nlmimage10 6d3a36a1
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
NebivololTablet2.5 mg/1OralAmerigen Pharmaceuticals Inc.2015-04-28Not applicableUs
NebivololTablet10 mg/1OralAmerigen Pharmaceuticals Inc.2015-04-28Not applicableUs
NebivololTablet5 mg/1OralAmerigen Pharmaceuticals Inc.2015-04-28Not applicableUs
NebivololTablet20 mg/1OralAmerigen Pharmaceuticals Inc.2015-04-28Not applicableUs
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
ByvalsonNebivolol hydrochloride (5 mg/1) + Valsartan (80 mg/1)Tablet, film coatedOralAllergan2016-06-03Not applicableUs
International/Other Brands
Lobivon / Nebicard / Nebilet / Nebilong / Nodon / Nubeta
Categories
UNII
030Y90569U
CAS number
118457-14-0
Weight
Average: 405.435
Monoisotopic: 405.175164703
Chemical Formula
C22H25F2NO4
InChI Key
KOHIRBRYDXPAMZ-UHFFFAOYSA-N
InChI
InChI=1S/C22H25F2NO4/c23-15-3-7-19-13(9-15)1-5-21(28-19)17(26)11-25-12-18(27)22-6-2-14-10-16(24)4-8-20(14)29-22/h3-4,7-10,17-18,21-22,25-27H,1-2,5-6,11-12H2
IUPAC Name
1-(6-fluoro-3,4-dihydro-2H-1-benzopyran-2-yl)-2-{[2-(6-fluoro-3,4-dihydro-2H-1-benzopyran-2-yl)-2-hydroxyethyl]amino}ethan-1-ol
SMILES
OC(CNCC(O)C1CCC2=C(O1)C=CC(F)=C2)C1CCC2=C(O1)C=CC(F)=C2

Pharmacology

Indication

For the treatment of essential hypertension.

Structured Indications
Pharmacodynamics

Nebivolol is a competitive and highly selective beta-1 receptor antagonist with mild vasodilating properties, possibly due to an interaction with the L-arginine/nitric oxide pathway. In preclinical studies, nebivolol has been shown to induce endothelium-dependent arterial relaxation in a dose dependent manner, by stimulation of the release of endothelial nitric oxide. Nitric oxide acts to relax vascular smooth muscle cells and inhibits platelet aggregation and adhesion.

Mechanism of action

Nebivolol is a selective β1-receptor antagonist. Activation of β1-receptors by epinephrine increases the heart rate and the blood pressure, and the heart consumes more oxygen. Nebivolol blocks these receptors which reverses the effects of epinephrine, lowering the heart rate and blood pressure. In addition, beta blockers prevent the release of renin, which is a hormone produced by the kidneys which leads to constriction of blood vessels. At high enough concentrations, this drug may also bind beta 2 receptors.

TargetActionsOrganism
ABeta-1 adrenergic receptor
antagonist
Human
UBeta-2 adrenergic receptor
antagonist
Human
Absorption

The absorption of nebivolol is rapid and not affected by food.

Volume of distribution
Not Available
Protein binding

98%

Metabolism

Hepatic (CYP2D6-mediated)

Route of elimination
Not Available
Half life

10 hours

Clearance
Not Available
Toxicity

The most common signs and symptoms associated with nebivolol overdosage are bradycardia and hypotension. Other important adverse events reported with nebivolol overdose include cardiac failure, dizziness, hypoglycemia, fatigue and vomiting. Other adverse events associated with β-blocker overdose include bronchospasm and heart block. The largest known ingestion of nebivolol worldwide involved a patient who ingested up to 500 mg of nebivolol along with several 100 mg tablets of acetylsalicylic acid in a suicide attempt. The patient experienced hyperhydrosis, pallor, depressed level of consciousness, hypokinesia, hypotension, sinus bradycardia, hypoglycemia, hypokalemia, respiratory failure and vomiting. The patient recovered.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Nebivolol Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Interacting Gene/EnzymeAllele nameGenotype(s)Defining Change(s)Type(s)DescriptionDetails
Cytochrome P450 2D6CYP2D6*3Not AvailableC alleleEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*4Not AvailableC alleleEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*5Not AvailableWhole-gene deletionEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*6Not Available1707delTEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*7Not Available2935A>CEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*8Not Available1758G>TEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*11Not Available883G>CEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*12Not Available124G>AEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*13Not AvailableCYP2D7/2D6 hybrid gene structureEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*14ANot Available1758G>AEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*15Not Available137insT, 137_138insTEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*19Not Available2539_2542delAACTEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*20Not Available1973_1974insGEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*21Not Available2573insCEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*31Not Available-1770G>A / -1584C>G  … show all Effect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*36Not Available100C>T / -1426C>T  … show all Effect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*38Not Available2587_2590delGACTEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*40Not Available1863_1864ins(TTT CGC CCC)2Effect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*42Not Available3259_3260insGTEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*44Not Available2950G>CEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*47Not Available100C>T / -1426C>T  … show all Effect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*51Not Available-1584C>G / -1235A>G  … show all Effect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*56Not Available3201C>TEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*57Not Available100C>T / 310G>T  … show all Effect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*62Not Available4044C>TEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*68ANot Available-1426C>T / -1235A>G  … show all Effect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*68BNot AvailableSimilar but not identical switch region compared to CYP2D6*68A. Found in tandem arrangement with CYP2D6*4.Effect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*69Not Available2988G>A / -1426C>T  … show all Effect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*92Not Available1995delCEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*100Not Available-1426C>T / -1235A>G  … show all Effect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*101Not Available-1426C>T / -1235A>G  … show all Effect InferredPoor drug metabolizer.Details

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limonene(4R)-limonene may decrease the antihypertensive activities of Nebivolol.Investigational
1,10-Phenanthroline1,10-Phenanthroline may increase the bradycardic activities of Nebivolol.Experimental
4-Methoxyamphetamine4-Methoxyamphetamine may increase the atrioventricular blocking (AV block) activities of Nebivolol.Experimental, Illicit
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Nebivolol.Experimental
AbirateroneThe serum concentration of Nebivolol can be increased when it is combined with Abiraterone.Approved
AcebutololAcebutolol may increase the hypotensive activities of Nebivolol.Approved, Investigational
AceclofenacAceclofenac may decrease the antihypertensive activities of Nebivolol.Approved, Investigational
AcemetacinThe therapeutic efficacy of Nebivolol can be decreased when used in combination with Acemetacin.Approved, Experimental, Investigational
AcepromazineAcepromazine may increase the hypotensive activities of Nebivolol.Approved, Vet Approved
AceprometazineAceprometazine may increase the hypotensive activities of Nebivolol.Approved
AcetohexamideNebivolol may increase the hypoglycemic activities of Acetohexamide.Approved, Investigational, Withdrawn
AcetylcholineThe risk or severity of adverse effects can be increased when Nebivolol is combined with Acetylcholine.Approved
AcetyldigitoxinNebivolol may increase the bradycardic activities of Acetyldigitoxin.Approved
AcetyldigoxinNebivolol may increase the bradycardic activities of Acetyldigoxin.Experimental
Acetylsalicylic acidAcetylsalicylic acid may decrease the antihypertensive activities of Nebivolol.Approved, Vet Approved
AdapaleneAdapalene may decrease the antihypertensive activities of Nebivolol.Approved
AgmatineAgmatine may increase the atrioventricular blocking (AV block) activities of Nebivolol.Experimental, Investigational
AlaproclateThe serum concentration of Nebivolol can be increased when it is combined with Alaproclate.Experimental
AlclofenacAlclofenac may decrease the antihypertensive activities of Nebivolol.Approved, Withdrawn
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Nebivolol.Approved
AlfentanilAlfentanil may increase the bradycardic activities of Nebivolol.Approved, Illicit
AlfuzosinAlfuzosin may increase the hypotensive activities of Nebivolol.Approved, Investigational
AlimemazineAlimemazine may increase the hypotensive activities of Nebivolol.Approved, Vet Approved
AliskirenNebivolol may increase the hypotensive activities of Aliskiren.Approved, Investigational
AlminoprofenAlminoprofen may decrease the antihypertensive activities of Nebivolol.Experimental
AlprenololAlprenolol may increase the hypotensive activities of Nebivolol.Approved, Withdrawn
AmbenoniumAmbenonium may increase the bradycardic activities of Nebivolol.Approved
AmbrisentanNebivolol may increase the hypotensive activities of Ambrisentan.Approved, Investigational
Ambroxol acefyllinateNebivolol may decrease the bronchodilatory activities of Ambroxol acefyllinate.Experimental, Investigational
AmifostineNebivolol may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Nebivolol.Approved
AminophyllineNebivolol may decrease the bronchodilatory activities of Aminophylline.Approved
AmiodaroneThe serum concentration of Nebivolol can be increased when it is combined with Amiodarone.Approved, Investigational
AmlodipineAmlodipine may increase the hypotensive activities of Nebivolol.Approved
AmobarbitalThe serum concentration of Nebivolol can be decreased when it is combined with Amobarbital.Approved, Illicit
AmodiaquineThe metabolism of Nebivolol can be decreased when combined with Amodiaquine.Approved, Investigational
AmphetamineAmphetamine may increase the hypotensive activities of Nebivolol.Approved, Illicit, Investigational
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Nebivolol.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Amyl Nitrite is combined with Nebivolol.Approved
AndrographolideAndrographolide may decrease the antihypertensive activities of Nebivolol.Investigational
AnisodamineAnisodamine may decrease the antihypertensive activities of Nebivolol.Investigational
AntipyrineAntipyrine may decrease the antihypertensive activities of Nebivolol.Approved, Investigational
ApocyninApocynin may decrease the antihypertensive activities of Nebivolol.Investigational
ApomorphineApomorphine may increase the atrioventricular blocking (AV block) activities of Nebivolol.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Apraclonidine is combined with Nebivolol.Approved
ApremilastApremilast may decrease the antihypertensive activities of Nebivolol.Approved, Investigational
ArbutamineNebivolol may decrease the bronchodilatory activities of Arbutamine.Approved
ArecolineThe risk or severity of adverse effects can be increased when Nebivolol is combined with Arecoline.Experimental
ArformoterolNebivolol may decrease the bronchodilatory activities of Arformoterol.Approved, Investigational
AripiprazoleAripiprazole may increase the hypotensive activities of Nebivolol.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Nebivolol.Investigational
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Nebivolol.Approved, Investigational
ArtemetherThe serum concentration of Nebivolol can be increased when it is combined with Artemether.Approved
AtenololAtenolol may increase the hypotensive activities of Nebivolol.Approved
AtomoxetineThe serum concentration of Nebivolol can be increased when it is combined with Atomoxetine.Approved
AvanafilAvanafil may increase the antihypertensive activities of Nebivolol.Approved
AzapropazoneAzapropazone may decrease the antihypertensive activities of Nebivolol.Withdrawn
AzelastineAzelastine may decrease the antihypertensive activities of Nebivolol.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Nebivolol is combined with Azilsartan medoxomil.Approved, Investigational
BalsalazideBalsalazide may decrease the antihypertensive activities of Nebivolol.Approved, Investigational
BambuterolNebivolol may decrease the bronchodilatory activities of Bambuterol.Approved, Investigational
BarbexacloneThe serum concentration of Nebivolol can be decreased when it is combined with Barbexaclone.Experimental
BarbitalThe serum concentration of Nebivolol can be decreased when it is combined with Barbital.Illicit
BarnidipineNebivolol may increase the antihypertensive activities of Barnidipine.Approved
BenazeprilBenazepril may increase the hypotensive activities of Nebivolol.Approved, Investigational
BendazacBendazac may decrease the antihypertensive activities of Nebivolol.Experimental
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of Nebivolol.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Nebivolol.Withdrawn
BenorilateBenorilate may decrease the antihypertensive activities of Nebivolol.Experimental
BenoxaprofenBenoxaprofen may decrease the antihypertensive activities of Nebivolol.Withdrawn
BenzphetamineBenzphetamine may increase the atrioventricular blocking (AV block) activities of Nebivolol.Approved, Illicit
BenzydamineBenzydamine may decrease the antihypertensive activities of Nebivolol.Approved
Benzylpenicilloyl PolylysineNebivolol may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
BepridilBepridil may increase the hypotensive activities of Nebivolol.Approved, Withdrawn
BeractantNebivolol may increase the bradycardic activities of Beractant.Approved
BetaxololThe serum concentration of Nebivolol can be increased when it is combined with Betaxolol.Approved, Investigational
BethanecholThe risk or severity of adverse effects can be increased when Nebivolol is combined with Bethanechol.Approved
BethanidineBethanidine may increase the atrioventricular blocking (AV block) activities of Nebivolol.Approved
BevoniumBevonium may decrease the antihypertensive activities of Nebivolol.Experimental
BietaserpineBietaserpine may increase the hypotensive activities of Nebivolol.Experimental
BimatoprostBimatoprost may increase the hypotensive activities of Nebivolol.Approved, Investigational
BisoprololBisoprolol may increase the hypotensive activities of Nebivolol.Approved
BL-1020BL-1020 may increase the hypotensive activities of Nebivolol.Investigational
BortezomibThe risk or severity of adverse effects can be increased when Bortezomib is combined with Nebivolol.Approved, Investigational
BosentanBosentan may increase the hypotensive activities of Nebivolol.Approved, Investigational
BQ-123Nebivolol may increase the hypotensive activities of BQ-123.Investigational
BretyliumBretylium may increase the bradycardic activities of Nebivolol.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Nebivolol.Approved
BrofaromineBrofaromine may increase the hypotensive activities of Nebivolol.Experimental
BromfenacBromfenac may decrease the antihypertensive activities of Nebivolol.Approved
BromocriptineBromocriptine may increase the hypertensive and vasoconstricting activities of Nebivolol.Approved, Investigational
BucillamineBucillamine may decrease the antihypertensive activities of Nebivolol.Investigational
BucindololNebivolol may increase the orthostatic hypotensive activities of Bucindolol.Investigational
BufexamacBufexamac may decrease the antihypertensive activities of Nebivolol.Approved, Experimental
BumadizoneBumadizone may decrease the antihypertensive activities of Nebivolol.Experimental
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Nebivolol.Approved
BunazosinNebivolol may increase the orthostatic hypotensive activities of Bunazosin.Investigational
BupivacaineThe serum concentration of Bupivacaine can be increased when it is combined with Nebivolol.Approved, Investigational
BupranololNebivolol may increase the hypotensive activities of Bupranolol.Approved
BupropionThe serum concentration of Nebivolol can be increased when it is combined with Bupropion.Approved
CabergolineCabergoline may increase the hypertensive and vasoconstricting activities of Nebivolol.Approved
CadralazineCadralazine may increase the hypotensive activities of Nebivolol.Experimental
CafedrineNebivolol may increase the hypotensive activities of Cafedrine.Investigational
Calcium carbimideThe risk or severity of adverse effects can be increased when Calcium carbimide is combined with Nebivolol.Approved, Withdrawn
CalfactantNebivolol may increase the bradycardic activities of Calfactant.Approved
CanagliflozinThe risk or severity of adverse effects can be increased when Nebivolol is combined with Canagliflozin.Approved
CandesartanNebivolol may increase the hypotensive activities of Candesartan.Experimental
Candesartan cilexetilCandesartan cilexetil may increase the hypotensive activities of Nebivolol.Approved
CandoxatrilCandoxatril may increase the hypotensive activities of Nebivolol.Experimental
CaptoprilCaptopril may increase the hypotensive activities of Nebivolol.Approved
CarbacholThe risk or severity of adverse effects can be increased when Nebivolol is combined with Carbachol.Approved
Carbaspirin calciumCarbaspirin calcium may decrease the antihypertensive activities of Nebivolol.Experimental, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Nebivolol.Approved, Investigational
CarbutamideNebivolol may increase the hypoglycemic activities of Carbutamide.Experimental
CaroxazoneCaroxazone may increase the hypotensive activities of Nebivolol.Withdrawn
CarprofenCarprofen may decrease the antihypertensive activities of Nebivolol.Approved, Vet Approved, Withdrawn
CarteololCarteolol may increase the hypotensive activities of Nebivolol.Approved
CarvedilolNebivolol may increase the orthostatic hypotensive activities of Carvedilol.Approved, Investigational
CastanospermineCastanospermine may decrease the antihypertensive activities of Nebivolol.Experimental
CelecoxibThe serum concentration of Nebivolol can be increased when it is combined with Celecoxib.Approved, Investigational
CeliprololCeliprolol may increase the hypotensive activities of Nebivolol.Approved, Investigational
CeritinibNebivolol may increase the bradycardic activities of Ceritinib.Approved
CevimelineThe risk or severity of adverse effects can be increased when Nebivolol is combined with Cevimeline.Approved
ChloroquineThe serum concentration of Nebivolol can be increased when it is combined with Chloroquine.Approved, Investigational, Vet Approved
ChlorothiazideChlorothiazide may increase the hypotensive activities of Nebivolol.Approved, Vet Approved
ChlorproethazineChlorproethazine may increase the hypotensive activities of Nebivolol.Experimental
ChlorpromazineThe serum concentration of Nebivolol can be increased when it is combined with Chlorpromazine.Approved, Investigational, Vet Approved
ChlorpropamideNebivolol may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Nebivolol.Approved
CholecalciferolThe serum concentration of Nebivolol can be increased when it is combined with Cholecalciferol.Approved, Nutraceutical
Choline magnesium trisalicylateCholine magnesium trisalicylate may decrease the antihypertensive activities of Nebivolol.Approved
CicletanineNebivolol may increase the hypotensive activities of Cicletanine.Investigational
CilazaprilCilazapril may increase the hypotensive activities of Nebivolol.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Nebivolol.Approved, Investigational
CimetidineThe serum concentration of Nebivolol can be increased when it is combined with Cimetidine.Approved, Investigational
CinacalcetThe serum concentration of Nebivolol can be increased when it is combined with Cinacalcet.Approved
CitalopramThe serum concentration of Nebivolol can be increased when it is combined with Citalopram.Approved
ClemastineThe serum concentration of Nebivolol can be increased when it is combined with Clemastine.Approved, Investigational
ClenbuterolNebivolol may decrease the bronchodilatory activities of Clenbuterol.Approved, Investigational, Vet Approved
ClevidipineThe risk or severity of adverse effects can be increased when Nebivolol is combined with Clevidipine.Approved, Investigational
ClobazamThe serum concentration of Nebivolol can be increased when it is combined with Clobazam.Approved, Illicit
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Nebivolol.Approved, Investigational
ClomipramineThe serum concentration of Nebivolol can be increased when it is combined with Clomipramine.Approved, Investigational, Vet Approved
ClonidineClonidine may increase the atrioventricular blocking (AV block) activities of Nebivolol.Approved
ClonixinClonixin may decrease the antihypertensive activities of Nebivolol.Approved
CloranololNebivolol may increase the hypotensive activities of Cloranolol.Experimental
ClotrimazoleThe serum concentration of Nebivolol can be increased when it is combined with Clotrimazole.Approved, Vet Approved
ClozapineThe serum concentration of Nebivolol can be increased when it is combined with Clozapine.Approved
CobicistatThe serum concentration of Nebivolol can be increased when it is combined with Cobicistat.Approved
CocaineThe serum concentration of Nebivolol can be increased when it is combined with Cocaine.Approved, Illicit
ConivaptanThe risk or severity of adverse effects can be increased when Conivaptan is combined with Nebivolol.Approved, Investigational
CoumaphosCoumaphos may increase the bradycardic activities of Nebivolol.Vet Approved
CrizotinibNebivolol may increase the bradycardic activities of Crizotinib.Approved
CryptenamineCryptenamine may increase the hypotensive activities of Nebivolol.Approved
CurcuminCurcumin may decrease the antihypertensive activities of Nebivolol.Approved, Investigational
CyclopenthiazideNebivolol may increase the hypotensive activities of Cyclopenthiazide.Experimental
CyclothiazideCyclothiazide may increase the hypotensive activities of Nebivolol.Approved
CymarinNebivolol may increase the bradycardic activities of Cymarin.Experimental
DapagliflozinThe risk or severity of adverse effects can be increased when Nebivolol is combined with Dapagliflozin.Approved
DapoxetineThe serum concentration of Nebivolol can be increased when it is combined with Dapoxetine.Investigational
DarifenacinThe serum concentration of Nebivolol can be increased when it is combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Nebivolol can be increased when it is combined with Darunavir.Approved
DebrisoquinDebrisoquin may increase the hypotensive activities of Nebivolol.Approved, Investigational
DecamethoniumDecamethonium may increase the bradycardic activities of Nebivolol.Approved
DelaprilNebivolol may increase the hypotensive activities of Delapril.Experimental
DelavirdineThe serum concentration of Nebivolol can be increased when it is combined with Delavirdine.Approved
DemecariumDemecarium may increase the bradycardic activities of Nebivolol.Approved
DeserpidineNebivolol may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Nebivolol.Approved
DesipramineThe serum concentration of Nebivolol can be increased when it is combined with Desipramine.Approved, Investigational
DeslanosideNebivolol may increase the bradycardic activities of Deslanoside.Approved
DesvenlafaxineDesvenlafaxine may increase the tachycardic activities of Nebivolol.Approved, Investigational
DexmedetomidineDexmedetomidine may increase the atrioventricular blocking (AV block) activities of Nebivolol.Approved, Vet Approved
DiazoxideDiazoxide may increase the hypotensive activities of Nebivolol.Approved
DichlorvosDichlorvos may increase the bradycardic activities of Nebivolol.Vet Approved
DiclofenacDiclofenac may decrease the antihypertensive activities of Nebivolol.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Nebivolol.Approved, Investigational
DiethylnorspermineNebivolol may increase the hypotensive activities of Diethylnorspermine.Investigational
DifenpiramideDifenpiramide may decrease the antihypertensive activities of Nebivolol.Experimental
DiflunisalDiflunisal may decrease the antihypertensive activities of Nebivolol.Approved, Investigational
DigitoxinNebivolol may increase the bradycardic activities of Digitoxin.Approved, Investigational
DigoxinNebivolol may increase the bradycardic activities of Digoxin.Approved
Digoxin Immune Fab (Ovine)Nebivolol may increase the bradycardic activities of Digoxin Immune Fab (Ovine).Approved
DihydralazineDihydralazine may increase the hypotensive activities of Nebivolol.Approved, Investigational
DihydroergotamineDihydroergotamine may increase the hypertensive and vasoconstricting activities of Nebivolol.Approved, Investigational
DiltiazemDiltiazem may increase the hypotensive activities of Nebivolol.Approved, Investigational
DinutuximabThe risk or severity of adverse effects can be increased when Nebivolol is combined with Dinutuximab.Approved, Investigational
DiphenhydramineThe serum concentration of Nebivolol can be increased when it is combined with Diphenhydramine.Approved, Investigational
DipivefrinDipivefrin may increase the atrioventricular blocking (AV block) activities of Nebivolol.Approved
DipyridamoleDipyridamole may increase the bradycardic activities of Nebivolol.Approved
DisopyramideDisopyramide may increase the bradycardic activities of Nebivolol.Approved
DistigmineDistigmine may increase the bradycardic activities of Nebivolol.Experimental
DobutamineNebivolol may decrease the bronchodilatory activities of Dobutamine.Approved
DonepezilDonepezil may increase the bradycardic activities of Nebivolol.Approved
DorzolamideDorzolamide may increase the hypotensive activities of Nebivolol.Approved
DosulepinThe serum concentration of Nebivolol can be increased when it is combined with Dosulepin.Approved
DoxazosinNebivolol may increase the orthostatic hypotensive activities of Doxazosin.Approved
DoxofyllineNebivolol may decrease the bronchodilatory activities of Doxofylline.Approved, Investigational
DronedaroneDronedarone may increase the bradycardic activities of Nebivolol.Approved
DroxicamDroxicam may decrease the antihypertensive activities of Nebivolol.Withdrawn
DroxidopaDroxidopa may increase the atrioventricular blocking (AV block) activities of Nebivolol.Approved, Investigational
DuloxetineThe serum concentration of Nebivolol can be increased when it is combined with Duloxetine.Approved
DuvelisibDuvelisib may decrease the antihypertensive activities of Nebivolol.Investigational
DyphyllineNebivolol may decrease the bronchodilatory activities of Dyphylline.Approved
E-6201E-6201 may decrease the antihypertensive activities of Nebivolol.Investigational
EchothiophateEchothiophate may increase the bradycardic activities of Nebivolol.Approved
EdrophoniumEdrophonium may increase the bradycardic activities of Nebivolol.Approved
EfonidipineNebivolol may increase the hypotensive activities of Efonidipine.Approved, Investigational
EliglustatThe serum concentration of Nebivolol can be increased when it is combined with Eliglustat.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Nebivolol is combined with Empagliflozin.Approved
EnalaprilEnalapril may increase the hypotensive activities of Nebivolol.Approved, Vet Approved
EnalaprilatNebivolol may increase the hypotensive activities of Enalaprilat.Approved
EndralazineEndralazine may increase the hypotensive activities of Nebivolol.Experimental
EpanololNebivolol may increase the hypotensive activities of Epanolol.Experimental
EphedraEphedra may increase the atrioventricular blocking (AV block) activities of Nebivolol.Approved, Nutraceutical, Withdrawn
EpibatidineThe risk or severity of adverse effects can be increased when Nebivolol is combined with Epibatidine.Experimental
EpinephrineEpinephrine may increase the atrioventricular blocking (AV block) activities of Nebivolol.Approved, Vet Approved
EpirizoleEpirizole may decrease the antihypertensive activities of Nebivolol.Approved
EplerenoneThe risk or severity of adverse effects can be increased when Eplerenone is combined with Nebivolol.Approved
EpoprostenolEpoprostenol may increase the hypotensive activities of Nebivolol.Approved
EprosartanEprosartan may increase the hypotensive activities of Nebivolol.Approved
Ergoloid mesylateErgoloid mesylate may increase the hypertensive and vasoconstricting activities of Nebivolol.Approved
ErgonovineErgonovine may increase the hypertensive and vasoconstricting activities of Nebivolol.Approved
ErgotamineErgotamine may increase the hypertensive and vasoconstricting activities of Nebivolol.Approved
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Nebivolol.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Nebivolol.Approved, Investigational
EtanerceptEtanercept may decrease the antihypertensive activities of Nebivolol.Approved, Investigational
EthenzamideEthenzamide may decrease the antihypertensive activities of Nebivolol.Experimental
EtodolacEtodolac may decrease the antihypertensive activities of Nebivolol.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may decrease the antihypertensive activities of Nebivolol.Approved, Investigational
EtomidateEtomidate may increase the atrioventricular blocking (AV block) activities of Nebivolol.Approved
EtoperidoneThe serum concentration of Nebivolol can be increased when it is combined with Etoperidone.Withdrawn
EtoricoxibEtoricoxib may decrease the antihypertensive activities of Nebivolol.Approved, Investigational
Evening primrose oilEvening primrose oil may decrease the antihypertensive activities of Nebivolol.Approved, Investigational
ExisulindExisulind may decrease the antihypertensive activities of Nebivolol.Investigational
FelbinacFelbinac may decrease the antihypertensive activities of Nebivolol.Experimental
FelodipineFelodipine may increase the hypotensive activities of Nebivolol.Approved, Investigational
FenbufenFenbufen may decrease the antihypertensive activities of Nebivolol.Approved
FenoldopamFenoldopam may increase the hypotensive activities of Nebivolol.Approved
FenoprofenFenoprofen may decrease the antihypertensive activities of Nebivolol.Approved
FenoterolNebivolol may decrease the bronchodilatory activities of Fenoterol.Approved, Investigational
FentanylFentanyl may increase the bradycardic activities of Nebivolol.Approved, Illicit, Investigational, Vet Approved
FenthionFenthion may increase the bradycardic activities of Nebivolol.Vet Approved
FentiazacFentiazac may decrease the antihypertensive activities of Nebivolol.Experimental
FeprazoneFeprazone may decrease the antihypertensive activities of Nebivolol.Experimental
Ferulic acidNebivolol may increase the hypotensive activities of Ferulic acid.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Nebivolol.Approved, Investigational
FingolimodNebivolol may increase the bradycardic activities of Fingolimod.Approved, Investigational
FloctafenineThe risk or severity of adverse effects can be increased when Nebivolol is combined with Floctafenine.Approved, Withdrawn
FlunixinFlunixin may decrease the antihypertensive activities of Nebivolol.Vet Approved
FlunoxaprofenFlunoxaprofen may decrease the antihypertensive activities of Nebivolol.Experimental
FluoxetineThe serum concentration of Nebivolol can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FluphenazineFluphenazine may increase the hypotensive activities of Nebivolol.Approved
FlurbiprofenFlurbiprofen may decrease the antihypertensive activities of Nebivolol.Approved, Investigational
FluvoxamineThe serum concentration of Nebivolol can be increased when it is combined with Fluvoxamine.Approved, Investigational
FormoterolNebivolol may decrease the bronchodilatory activities of Formoterol.Approved, Investigational
FosinoprilFosinopril may increase the hypotensive activities of Nebivolol.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Nebivolol.Approved, Investigational, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Nebivolol.Approved, Vet Approved
GalantamineGalantamine may increase the bradycardic activities of Nebivolol.Approved
Gallamine TriethiodideGallamine Triethiodide may increase the bradycardic activities of Nebivolol.Approved
GitoformateNebivolol may increase the bradycardic activities of Gitoformate.Experimental
GlibornurideNebivolol may increase the hypoglycemic activities of Glibornuride.Investigational, Withdrawn
GliclazideNebivolol may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideNebivolol may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideNebivolol may increase the hypoglycemic activities of Glipizide.Approved, Investigational
GliquidoneNebivolol may increase the hypoglycemic activities of Gliquidone.Approved, Investigational
GlisoxepideNebivolol may increase the hypoglycemic activities of Glisoxepide.Investigational
GlyburideNebivolol may increase the hypoglycemic activities of Glyburide.Approved
GTS-21The risk or severity of adverse effects can be increased when Nebivolol is combined with GTS-21.Investigational
GuacetisalGuacetisal may decrease the antihypertensive activities of Nebivolol.Experimental
GuanabenzGuanabenz may increase the atrioventricular blocking (AV block) activities of Nebivolol.Approved, Investigational
GuanadrelGuanadrel may increase the hypotensive activities of Nebivolol.Approved
GuanazodineNebivolol may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineGuanethidine may increase the hypotensive activities of Nebivolol.Approved
GuanfacineGuanfacine may increase the atrioventricular blocking (AV block) activities of Nebivolol.Approved, Investigational
GuanoclorNebivolol may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzNebivolol may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanNebivolol may increase the hypotensive activities of Guanoxan.Experimental
HaloperidolThe serum concentration of Nebivolol can be increased when it is combined with Haloperidol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Nebivolol.Approved, Vet Approved
HarmalineHarmaline may increase the hypotensive activities of Nebivolol.Experimental
HexamethoniumNebivolol may increase the hypotensive activities of Hexamethonium.Experimental
HexobarbitalThe serum concentration of Nebivolol can be decreased when it is combined with Hexobarbital.Approved
HigenamineHigenamine may decrease the antihypertensive activities of Nebivolol.Investigational
Huperzine AHuperzine A may increase the bradycardic activities of Nebivolol.Approved, Investigational
HydracarbazineHydracarbazine may increase the hypotensive activities of Nebivolol.Experimental
HydralazineHydralazine may increase the hypotensive activities of Nebivolol.Approved
HydrochlorothiazideHydrochlorothiazide may increase the hypotensive activities of Nebivolol.Approved, Vet Approved
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Nebivolol.Approved, Investigational
HydroxychloroquineThe metabolism of Nebivolol can be decreased when combined with Hydroxychloroquine.Approved
IbuprofenIbuprofen may decrease the antihypertensive activities of Nebivolol.Approved
IbuproxamIbuproxam may decrease the antihypertensive activities of Nebivolol.Withdrawn
IcatibantIcatibant may decrease the antihypertensive activities of Nebivolol.Approved, Investigational
IloprostThe risk or severity of adverse effects can be increased when Iloprost is combined with Nebivolol.Approved, Investigational
ImidaprilNebivolol may increase the hypotensive activities of Imidapril.Investigational
Imidazole salicylateImidazole salicylate may decrease the antihypertensive activities of Nebivolol.Experimental
ImipramineThe serum concentration of Nebivolol can be increased when it is combined with Imipramine.Approved
IndacaterolNebivolol may decrease the bronchodilatory activities of Indacaterol.Approved
IndalpineThe serum concentration of Nebivolol can be increased when it is combined with Indalpine.Investigational, Withdrawn
IndapamideIndapamide may increase the hypotensive activities of Nebivolol.Approved
IndenololNebivolol may increase the hypotensive activities of Indenolol.Withdrawn
IndinavirThe serum concentration of Nebivolol can be increased when it is combined with Indinavir.Approved
IndobufenIndobufen may decrease the antihypertensive activities of Nebivolol.Investigational
IndomethacinIndomethacin may decrease the antihypertensive activities of Nebivolol.Approved, Investigational
IndoprofenIndoprofen may decrease the antihypertensive activities of Nebivolol.Withdrawn
IndoraminNebivolol may increase the orthostatic hypotensive activities of Indoramin.Withdrawn
Insulin HumanNebivolol may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin PorkNebivolol may increase the hypoglycemic activities of Insulin Pork.Approved
IpidacrineIpidacrine may increase the bradycardic activities of Nebivolol.Experimental
IproclozideIproclozide may increase the hypotensive activities of Nebivolol.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Nebivolol.Withdrawn
IrbesartanIrbesartan may increase the hypotensive activities of Nebivolol.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Nebivolol.Approved
IsoetarineNebivolol may decrease the bronchodilatory activities of Isoetarine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Nebivolol.Approved, Vet Approved
IsoflurophateIsoflurophate may increase the bradycardic activities of Nebivolol.Approved, Investigational, Withdrawn
IsoniazidThe serum concentration of Nebivolol can be increased when it is combined with Isoniazid.Approved, Investigational
IsoprenalineNebivolol may decrease the bronchodilatory activities of Isoprenaline.Approved, Investigational
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Nebivolol.Approved, Investigational
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Nebivolol.Approved
IsoxicamIsoxicam may decrease the antihypertensive activities of Nebivolol.Withdrawn
IsoxsuprineThe risk or severity of adverse effects can be increased when Nebivolol is combined with Isoxsuprine.Approved, Withdrawn
IsradipineIsradipine may increase the hypotensive activities of Nebivolol.Approved, Investigational
IvabradineNebivolol may increase the bradycardic activities of Ivabradine.Approved
KebuzoneKebuzone may decrease the antihypertensive activities of Nebivolol.Experimental
KetanserinKetanserin may increase the hypotensive activities of Nebivolol.Investigational
KetoconazoleThe serum concentration of Nebivolol can be increased when it is combined with Ketoconazole.Approved, Investigational
KetoprofenKetoprofen may decrease the antihypertensive activities of Nebivolol.Approved, Vet Approved
KetorolacKetorolac may decrease the antihypertensive activities of Nebivolol.Approved
LabetalolNebivolol may increase the orthostatic hypotensive activities of Labetalol.Approved
LacidipineNebivolol may increase the hypotensive activities of Lacidipine.Approved, Investigational
LacosamideNebivolol may increase the atrioventricular blocking (AV block) activities of Lacosamide.Approved
Lanatoside CNebivolol may increase the bradycardic activities of Lanatoside C.Experimental
LanreotideNebivolol may increase the bradycardic activities of Lanreotide.Approved
LatanoprostLatanoprost may increase the hypotensive activities of Nebivolol.Approved, Investigational
LeflunomideLeflunomide may decrease the antihypertensive activities of Nebivolol.Approved, Investigational
LercanidipineLercanidipine may increase the hypotensive activities of Nebivolol.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Levobunolol is combined with Nebivolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Nebivolol.Approved, Investigational
LevodopaNebivolol may increase the orthostatic hypotensive activities of Levodopa.Approved
LevomilnacipranLevomilnacipran may increase the tachycardic activities of Nebivolol.Approved, Investigational
LevonordefrinLevonordefrin may increase the atrioventricular blocking (AV block) activities of Nebivolol.Approved
LevosalbutamolNebivolol may decrease the bronchodilatory activities of Levosalbutamol.Approved, Investigational
LevosimendanThe risk or severity of adverse effects can be increased when Levosimendan is combined with Nebivolol.Approved, Investigational
LidocaineThe serum concentration of Lidocaine can be increased when it is combined with Nebivolol.Approved, Vet Approved
LinsidomineNebivolol may increase the hypotensive activities of Linsidomine.Experimental
LisinoprilLisinopril may increase the hypotensive activities of Nebivolol.Approved, Investigational
LisofyllineLisofylline may decrease the antihypertensive activities of Nebivolol.Investigational
LobelineThe risk or severity of adverse effects can be increased when Nebivolol is combined with Lobeline.Investigational
LofexidineLofexidine may increase the atrioventricular blocking (AV block) activities of Nebivolol.Approved, Investigational
LonazolacLonazolac may decrease the antihypertensive activities of Nebivolol.Experimental
LopinavirThe serum concentration of Nebivolol can be increased when it is combined with Lopinavir.Approved
LorcaserinThe serum concentration of Nebivolol can be increased when it is combined with Lorcaserin.Approved
LornoxicamLornoxicam may decrease the antihypertensive activities of Nebivolol.Approved, Investigational
LorpiprazoleThe therapeutic efficacy of Nebivolol can be increased when used in combination with Lorpiprazole.Approved
LosartanLosartan may increase the hypotensive activities of Nebivolol.Approved
LoxoprofenLoxoprofen may decrease the antihypertensive activities of Nebivolol.Approved, Investigational
LucinactantNebivolol may increase the bradycardic activities of Lucinactant.Approved, Investigational
LumefantrineThe serum concentration of Nebivolol can be increased when it is combined with Lumefantrine.Approved
LumiracoxibLumiracoxib may decrease the antihypertensive activities of Nebivolol.Approved, Investigational
MacitentanNebivolol may increase the hypotensive activities of Macitentan.Approved
Magnesium salicylateMagnesium salicylate may decrease the antihypertensive activities of Nebivolol.Approved
MalathionMalathion may increase the bradycardic activities of Nebivolol.Approved, Investigational
ManidipineThe serum concentration of Nebivolol can be increased when it is combined with Manidipine.Approved, Investigational
MannitolThe risk or severity of adverse effects can be increased when Mannitol is combined with Nebivolol.Approved, Investigational
MasoprocolMasoprocol may decrease the antihypertensive activities of Nebivolol.Approved, Investigational
MebanazineMebanazine may increase the hypotensive activities of Nebivolol.Withdrawn
MecamylamineMecamylamine may increase the hypotensive activities of Nebivolol.Approved, Investigational
Meclofenamic acidMeclofenamic acid may decrease the antihypertensive activities of Nebivolol.Approved, Vet Approved
Mefenamic acidMefenamic acid may decrease the antihypertensive activities of Nebivolol.Approved
MefloquineMefloquine may increase the bradycardic activities of Nebivolol.Approved, Investigational
MeloxicamMeloxicam may decrease the antihypertensive activities of Nebivolol.Approved, Vet Approved
MemantineMemantine may increase the bradycardic activities of Nebivolol.Approved, Investigational
MepivacaineThe serum concentration of Mepivacaine can be increased when it is combined with Nebivolol.Approved, Vet Approved
MesalazineMesalazine may decrease the antihypertensive activities of Nebivolol.Approved
MesoridazineMesoridazine may increase the hypotensive activities of Nebivolol.Approved, Investigational
MetahexamideNebivolol may increase the hypoglycemic activities of Metahexamide.Experimental
MetamizoleMetamizole may decrease the antihypertensive activities of Nebivolol.Approved, Investigational, Withdrawn
MethacholineNebivolol may increase the bronchoconstrictory activities of Methacholine.Approved, Investigational
MethadoneThe serum concentration of Nebivolol can be increased when it is combined with Methadone.Approved
MethamphetamineMethamphetamine may increase the atrioventricular blocking (AV block) activities of Nebivolol.Approved, Illicit
Methanesulfonyl FluorideMethanesulfonyl Fluoride may increase the bradycardic activities of Nebivolol.Investigational
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Nebivolol.Approved
MethohexitalThe serum concentration of Nebivolol can be decreased when it is combined with Methohexital.Approved
MethoserpidineNebivolol may increase the hypotensive activities of Methoserpidine.Experimental
MethotrimeprazineThe serum concentration of Nebivolol can be increased when it is combined with Methotrimeprazine.Approved, Investigational
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Nebivolol.Approved
MethyldopaMethyldopa may increase the hypotensive activities of Nebivolol.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Nebivolol.Approved, Investigational
MethylergometrineMethylergometrine may increase the hypertensive and vasoconstricting activities of Nebivolol.Approved
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Nebivolol.Approved, Investigational
MethylphenobarbitalThe serum concentration of Nebivolol can be decreased when it is combined with Methylphenobarbital.Approved
MetildigoxinNebivolol may increase the bradycardic activities of Metildigoxin.Experimental
MetipranololMetipranolol may increase the hypotensive activities of Nebivolol.Approved
MetoclopramideMetoclopramide may increase the bradycardic activities of Nebivolol.Approved, Investigational
MetolazoneMetolazone may increase the hypotensive activities of Nebivolol.Approved
MetoprololThe serum concentration of Nebivolol can be increased when it is combined with Metoprolol.Approved, Investigational
MetyrosineNebivolol may increase the hypotensive activities of Metyrosine.Approved
MibefradilMibefradil may increase the hypotensive activities of Nebivolol.Investigational, Withdrawn
MidodrineNebivolol may increase the bradycardic activities of Midodrine.Approved
MidostaurinThe serum concentration of Nebivolol can be increased when it is combined with Midostaurin.Approved, Investigational
MilnacipranMilnacipran may increase the tachycardic activities of Nebivolol.Approved, Investigational
MinaprineMinaprine may increase the hypotensive activities of Nebivolol.Approved
MinoxidilMinoxidil may increase the hypotensive activities of Nebivolol.Approved, Investigational
MirabegronThe serum concentration of Nebivolol can be increased when it is combined with Mirabegron.Approved
MirodenafilMirodenafil may increase the antihypertensive activities of Nebivolol.Investigational
MizoribineMizoribine may decrease the antihypertensive activities of Nebivolol.Investigational
MoclobemideMoclobemide may increase the hypotensive activities of Nebivolol.Approved, Investigational
MoexiprilMoexipril may increase the hypotensive activities of Nebivolol.Approved
MofebutazoneMofebutazone may decrease the antihypertensive activities of Nebivolol.Experimental
MolsidomineMolsidomine may increase the hypotensive activities of Nebivolol.Approved, Investigational
MoricizineMoricizine may increase the hypotensive activities of Nebivolol.Approved, Investigational, Withdrawn
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Nebivolol.Approved, Investigational
MoxonidineMoxonidine may increase the atrioventricular blocking (AV block) activities of Nebivolol.Approved, Investigational
MuzolimineNebivolol may increase the hypotensive activities of Muzolimine.Experimental
Mycophenolate mofetilMycophenolate mofetil may decrease the antihypertensive activities of Nebivolol.Approved, Investigational
Mycophenolic acidMycophenolic acid may decrease the antihypertensive activities of Nebivolol.Approved
NabiloneThe risk or severity of adverse effects can be increased when Nabilone is combined with Nebivolol.Approved, Investigational
NabumetoneNabumetone may decrease the antihypertensive activities of Nebivolol.Approved
NadololNadolol may increase the hypotensive activities of Nebivolol.Approved
NafamostatNafamostat may decrease the antihypertensive activities of Nebivolol.Approved, Investigational
NaftifineNaftifine may decrease the antihypertensive activities of Nebivolol.Approved
NaftopidilNebivolol may increase the hypotensive activities of Naftopidil.Investigational
NaphazolineNaphazoline may increase the atrioventricular blocking (AV block) activities of Nebivolol.Approved
NaproxenNaproxen may decrease the antihypertensive activities of Nebivolol.Approved, Vet Approved
NefazodoneThe serum concentration of Nebivolol can be increased when it is combined with Nefazodone.Approved, Withdrawn
NeostigmineNeostigmine may increase the bradycardic activities of Nebivolol.Approved, Vet Approved
NepafenacNepafenac may decrease the antihypertensive activities of Nebivolol.Approved, Investigational
NesiritideThe risk or severity of adverse effects can be increased when Nebivolol is combined with Nesiritide.Approved, Investigational
NevirapineThe serum concentration of Nebivolol can be increased when it is combined with Nevirapine.Approved
NialamideNialamide may increase the hypotensive activities of Nebivolol.Withdrawn
NicardipineThe serum concentration of Nebivolol can be increased when it is combined with Nicardipine.Approved, Investigational
NicorandilNicorandil may increase the hypotensive activities of Nebivolol.Approved, Investigational
NicotineThe risk or severity of adverse effects can be increased when Nebivolol is combined with Nicotine.Approved
NifedipineThe risk or severity of congestive heart failure and hypotension can be increased when Nifedipine is combined with Nebivolol.Approved
NifenazoneNifenazone may decrease the antihypertensive activities of Nebivolol.Experimental
Niflumic AcidNiflumic Acid may decrease the antihypertensive activities of Nebivolol.Approved
NiguldipineNebivolol may increase the hypotensive activities of Niguldipine.Experimental
NilotinibThe serum concentration of Nebivolol can be increased when it is combined with Nilotinib.Approved, Investigational
NilvadipineNebivolol may increase the hypotensive activities of Nilvadipine.Approved, Investigational
NimesulideNimesulide may decrease the antihypertensive activities of Nebivolol.Approved, Investigational, Withdrawn
NimodipineNimodipine may increase the hypotensive activities of Nebivolol.Approved, Investigational
NisoldipineNisoldipine may increase the hypotensive activities of Nebivolol.Approved
NitrendipineNitrendipine may increase the hypotensive activities of Nebivolol.Approved, Investigational
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Nebivolol.Approved
NitroaspirinNitroaspirin may decrease the antihypertensive activities of Nebivolol.Investigational
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Nebivolol.Approved, Investigational
NitroprussideNitroprusside may increase the hypotensive activities of Nebivolol.Approved, Investigational
Nitrous acidThe risk or severity of adverse effects can be increased when Nitrous acid is combined with Nebivolol.Approved, Investigational
NorepinephrineNorepinephrine may increase the atrioventricular blocking (AV block) activities of Nebivolol.Approved
ObinutuzumabNebivolol may increase the hypotensive activities of Obinutuzumab.Approved, Investigational
OctamoxinOctamoxin may increase the hypotensive activities of Nebivolol.Withdrawn
OctreotideOctreotide may increase the bradycardic activities of Nebivolol.Approved, Investigational
OleandrinNebivolol may increase the bradycardic activities of Oleandrin.Experimental, Investigational
OlmesartanOlmesartan may increase the hypotensive activities of Nebivolol.Approved, Investigational
OlodaterolNebivolol may decrease the bronchodilatory activities of Olodaterol.Approved
OlopatadineOlopatadine may decrease the antihypertensive activities of Nebivolol.Approved
OlsalazineOlsalazine may decrease the antihypertensive activities of Nebivolol.Approved
OmapatrilatOmapatrilat may increase the hypotensive activities of Nebivolol.Investigational
OrciprenalineNebivolol may decrease the bronchodilatory activities of Orciprenaline.Approved
OrgoteinOrgotein may decrease the antihypertensive activities of Nebivolol.Vet Approved
OuabainNebivolol may increase the bradycardic activities of Ouabain.Approved
OxaprozinOxaprozin may decrease the antihypertensive activities of Nebivolol.Approved
OxprenololOxprenolol may increase the hypotensive activities of Nebivolol.Approved
OxymetazolineOxymetazoline may increase the atrioventricular blocking (AV block) activities of Nebivolol.Approved, Investigational
OxyphenbutazoneOxyphenbutazone may decrease the antihypertensive activities of Nebivolol.Approved, Withdrawn
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Nebivolol.Approved, Vet Approved
PaliperidonePaliperidone may increase the atrioventricular blocking (AV block) activities of Nebivolol.Approved
PanobinostatThe serum concentration of Nebivolol can be increased when it is combined with Panobinostat.Approved, Investigational
PapaverineThe risk or severity of adverse effects can be increased when Papaverine is combined with Nebivolol.Approved, Investigational
ParaoxonParaoxon may increase the bradycardic activities of Nebivolol.Experimental
ParecoxibParecoxib may decrease the antihypertensive activities of Nebivolol.Approved
PargylinePargyline may increase the hypotensive activities of Nebivolol.Approved
ParoxetineThe serum concentration of Nebivolol can be increased when it is combined with Paroxetine.Approved, Investigational
ParthenolideParthenolide may decrease the antihypertensive activities of Nebivolol.Approved, Investigational
PasireotideNebivolol may increase the bradycardic activities of Pasireotide.Approved
Peginterferon alfa-2bThe serum concentration of Nebivolol can be decreased when it is combined with Peginterferon alfa-2b.Approved
PenbutololPenbutolol may increase the hypotensive activities of Nebivolol.Approved, Investigational
PentobarbitalThe serum concentration of Nebivolol can be decreased when it is combined with Pentobarbital.Approved, Investigational, Vet Approved
PentoliniumPentolinium may increase the hypotensive activities of Nebivolol.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Nebivolol.Approved, Investigational
PerazinePerazine may increase the hypotensive activities of Nebivolol.Approved, Investigational
PergolidePergolide may increase the atrioventricular blocking (AV block) activities of Nebivolol.Approved, Investigational, Vet Approved, Withdrawn
PerindoprilPerindopril may increase the hypotensive activities of Nebivolol.Approved
PerphenazinePerphenazine may increase the hypotensive activities of Nebivolol.Approved
PeruvosideNebivolol may increase the bradycardic activities of Peruvoside.Experimental
PhenelzinePhenelzine may increase the hypotensive activities of Nebivolol.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Nebivolol.Withdrawn
PhenobarbitalThe serum concentration of Nebivolol can be decreased when it is combined with Phenobarbital.Approved, Investigational
PhenoxybenzaminePhenoxybenzamine may increase the hypotensive activities of Nebivolol.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Nebivolol.Withdrawn
PhentolaminePhentolamine may increase the hypotensive activities of Nebivolol.Approved
PhenylbutazonePhenylbutazone may decrease the antihypertensive activities of Nebivolol.Approved, Vet Approved
PhenylpropanolamineNebivolol may decrease the bronchodilatory activities of Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PhysostigminePhysostigmine may increase the bradycardic activities of Nebivolol.Approved, Investigational
PilocarpineThe risk or severity of adverse effects can be increased when Nebivolol is combined with Pilocarpine.Approved, Investigational
PimecrolimusPimecrolimus may decrease the antihypertensive activities of Nebivolol.Approved, Investigational
PinacidilPinacidil may increase the hypotensive activities of Nebivolol.Approved
PindololPindolol may increase the hypotensive activities of Nebivolol.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Nebivolol.Approved, Investigational
PirbuterolNebivolol may decrease the bronchodilatory activities of Pirbuterol.Approved
PirfenidonePirfenidone may decrease the antihypertensive activities of Nebivolol.Approved, Investigational
PirlindolePirlindole may increase the hypotensive activities of Nebivolol.Approved
PiroxicamPiroxicam may decrease the antihypertensive activities of Nebivolol.Approved, Investigational
PirprofenPirprofen may decrease the antihypertensive activities of Nebivolol.Experimental
PitolisantThe serum concentration of Nebivolol can be increased when it is combined with Pitolisant.Approved, Investigational
PivhydrazinePivhydrazine may increase the hypotensive activities of Nebivolol.Withdrawn
Platelet Activating FactorPlatelet Activating Factor may increase the hypotensive activities of Nebivolol.Experimental
PolythiazidePolythiazide may increase the hypotensive activities of Nebivolol.Approved
Poractant alfaNebivolol may increase the bradycardic activities of Poractant alfa.Approved
PramipexoleThe risk or severity of adverse effects can be increased when Pramipexole is combined with Nebivolol.Approved, Investigational
PranoprofenPranoprofen may decrease the antihypertensive activities of Nebivolol.Experimental, Investigational
PrazosinNebivolol may increase the orthostatic hypotensive activities of Prazosin.Approved
PrimaquineThe metabolism of Nebivolol can be decreased when combined with Primaquine.Approved
PrimidoneThe serum concentration of Nebivolol can be decreased when it is combined with Primidone.Approved, Vet Approved
ProcarbazineProcarbazine may increase the hypotensive activities of Nebivolol.Approved, Investigational
ProcaterolNebivolol may decrease the bronchodilatory activities of Procaterol.Approved, Investigational
ProchlorperazineProchlorperazine may increase the hypotensive activities of Nebivolol.Approved, Vet Approved
ProglumetacinProglumetacin may decrease the antihypertensive activities of Nebivolol.Experimental
PromazineThe serum concentration of Nebivolol can be increased when it is combined with Promazine.Approved, Vet Approved
PromethazinePromethazine may increase the hypotensive activities of Nebivolol.Approved, Investigational
PropacetamolPropacetamol may decrease the antihypertensive activities of Nebivolol.Approved, Investigational
PropafenoneThe serum concentration of Nebivolol can be increased when it is combined with Propafenone.Approved
PropericiazinePropericiazine may increase the hypotensive activities of Nebivolol.Approved, Investigational
PropiopromazinePropiopromazine may increase the hypotensive activities of Nebivolol.Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Nebivolol.Approved, Investigational, Vet Approved
PropranololPropranolol may increase the hypotensive activities of Nebivolol.Approved, Investigational
PropyphenazonePropyphenazone may decrease the antihypertensive activities of Nebivolol.Experimental
ProquazoneProquazone may decrease the antihypertensive activities of Nebivolol.Experimental
ProscillaridinNebivolol may increase the bradycardic activities of Proscillaridin.Experimental
ProtokylolNebivolol may decrease the bronchodilatory activities of Protokylol.Approved, Vet Approved
PseudoephedrinePseudoephedrine may increase the atrioventricular blocking (AV block) activities of Nebivolol.Approved
PTC299PTC299 may decrease the antihypertensive activities of Nebivolol.Investigational
PyridostigminePyridostigmine may increase the bradycardic activities of Nebivolol.Approved, Investigational
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Nebivolol.Approved
QuinaprilQuinapril may increase the hypotensive activities of Nebivolol.Approved, Investigational
QuinidineThe serum concentration of Nebivolol can be increased when it is combined with Quinidine.Approved, Investigational
QuinineThe serum concentration of Nebivolol can be increased when it is combined with Quinine.Approved
RacepinephrineRacepinephrine may increase the atrioventricular blocking (AV block) activities of Nebivolol.Approved
RamiprilRamipril may increase the hypotensive activities of Nebivolol.Approved
RanolazineThe serum concentration of Nebivolol can be increased when it is combined with Ranolazine.Approved, Investigational
RasagilineRasagiline may increase the hypotensive activities of Nebivolol.Approved
RegorafenibRegorafenib may increase the bradycardic activities of Nebivolol.Approved
RemifentanilRemifentanil may increase the bradycardic activities of Nebivolol.Approved
RemikirenRemikiren may increase the hypotensive activities of Nebivolol.Approved
RescinnamineNebivolol may increase the hypotensive activities of Rescinnamine.Approved
ReserpineReserpine may increase the hypotensive activities of Nebivolol.Approved, Investigational
ResveratrolResveratrol may decrease the antihypertensive activities of Nebivolol.Approved, Experimental, Investigational
RifampicinThe serum concentration of Nebivolol can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Nebivolol can be decreased when it is combined with Rifapentine.Approved, Investigational
RifaximinThe serum concentration of Nebivolol can be decreased when it is combined with Rifaximin.Approved, Investigational
RilmenidineRilmenidine may increase the hypotensive activities of Nebivolol.Approved, Investigational
RiociguatNebivolol may increase the hypotensive activities of Riociguat.Approved
RisperidoneNebivolol may increase the hypotensive activities of Risperidone.Approved, Investigational
RitodrineNebivolol may decrease the bronchodilatory activities of Ritodrine.Approved, Investigational
RitonavirThe serum concentration of Nebivolol can be increased when it is combined with Ritonavir.Approved, Investigational
RituximabNebivolol may increase the hypotensive activities of Rituximab.Approved
RivastigmineNebivolol may increase the bradycardic activities of Rivastigmine.Approved, Investigational
RofecoxibRofecoxib may decrease the antihypertensive activities of Nebivolol.Approved, Investigational, Withdrawn
RolapitantThe serum concentration of Nebivolol can be increased when it is combined with Rolapitant.Approved, Investigational
RopiniroleThe serum concentration of Nebivolol can be increased when it is combined with Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Nebivolol.Approved
RotigotineThe risk or severity of adverse effects can be increased when Rotigotine is combined with Nebivolol.Approved
RucaparibThe serum concentration of Nebivolol can be increased when it is combined with Rucaparib.Approved, Investigational
RuxolitinibRuxolitinib may increase the bradycardic activities of Nebivolol.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Nebivolol.Approved
SafrazineSafrazine may increase the hypotensive activities of Nebivolol.Withdrawn
SalbutamolNebivolol may decrease the bronchodilatory activities of Salbutamol.Approved, Vet Approved
SalicylamideSalicylamide may decrease the antihypertensive activities of Nebivolol.Approved
Salicylic acidSalicylic acid may decrease the antihypertensive activities of Nebivolol.Approved, Investigational, Vet Approved
SalmeterolNebivolol may decrease the bronchodilatory activities of Salmeterol.Approved
SalsalateSalsalate may decrease the antihypertensive activities of Nebivolol.Approved
SaprisartanSaprisartan may increase the hypotensive activities of Nebivolol.Experimental
SecobarbitalThe serum concentration of Nebivolol can be decreased when it is combined with Secobarbital.Approved, Vet Approved
SelegilineSelegiline may increase the hypotensive activities of Nebivolol.Approved, Investigational, Vet Approved
SelexipagNebivolol may increase the hypotensive activities of Selexipag.Approved
SemapimodSemapimod may decrease the antihypertensive activities of Nebivolol.Investigational
SeratrodastSeratrodast may decrease the antihypertensive activities of Nebivolol.Approved
SerrapeptaseSerrapeptase may decrease the antihypertensive activities of Nebivolol.Investigational
SertralineThe serum concentration of Nebivolol can be increased when it is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Nebivolol.Approved, Vet Approved
SildenafilSildenafil may increase the antihypertensive activities of Nebivolol.Approved, Investigational
SilodosinNebivolol may increase the orthostatic hypotensive activities of Silodosin.Approved
SitaxentanNebivolol may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Nebivolol.Approved
SpiraprilSpirapril may increase the hypotensive activities of Nebivolol.Approved
SpironolactoneSpironolactone may decrease the vasoconstricting activities of Nebivolol.Approved
SRT501SRT501 may decrease the antihypertensive activities of Nebivolol.Investigational
StiripentolThe serum concentration of Nebivolol can be increased when it is combined with Stiripentol.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Streptokinase is combined with Nebivolol.Approved, Investigational
SufentanilSufentanil may increase the bradycardic activities of Nebivolol.Approved, Investigational
SulfasalazineSulfasalazine may decrease the antihypertensive activities of Nebivolol.Approved
SulindacSulindac may decrease the antihypertensive activities of Nebivolol.Approved, Investigational
SuprofenSuprofen may decrease the antihypertensive activities of Nebivolol.Approved, Withdrawn
SuxibuzoneSuxibuzone may decrease the antihypertensive activities of Nebivolol.Experimental
TacrineTacrine may increase the bradycardic activities of Nebivolol.Investigational, Withdrawn
TadalafilTadalafil may increase the antihypertensive activities of Nebivolol.Approved, Investigational
TalinololNebivolol may increase the hypotensive activities of Talinolol.Investigational
TamsulosinNebivolol may increase the orthostatic hypotensive activities of Tamsulosin.Approved, Investigational
TarenflurbilTarenflurbil may decrease the antihypertensive activities of Nebivolol.Investigational
TelmisartanTelmisartan may increase the hypotensive activities of Nebivolol.Approved, Investigational
TemocaprilNebivolol may increase the hypotensive activities of Temocapril.Experimental, Investigational
TenidapTenidap may decrease the antihypertensive activities of Nebivolol.Experimental
TenoxicamTenoxicam may decrease the antihypertensive activities of Nebivolol.Approved
TepoxalinTepoxalin may decrease the antihypertensive activities of Nebivolol.Vet Approved
TerazosinNebivolol may increase the orthostatic hypotensive activities of Terazosin.Approved
TerbinafineThe serum concentration of Nebivolol can be increased when it is combined with Terbinafine.Approved, Investigational, Vet Approved
TerbutalineNebivolol may decrease the bronchodilatory activities of Terbutaline.Approved
TeriflunomideTeriflunomide may decrease the antihypertensive activities of Nebivolol.Approved
TerlipressinTerlipressin may increase the hypotensive activities of Nebivolol.Approved, Investigational
TetrahydropalmatineNebivolol may increase the hypotensive activities of Tetrahydropalmatine.Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Nebivolol.Approved, Investigational, Withdrawn
TheodrenalineNebivolol may increase the hypotensive activities of Theodrenaline.Investigational
TheophyllineNebivolol may decrease the bronchodilatory activities of Theophylline.Approved
ThiamylalThe serum concentration of Nebivolol can be decreased when it is combined with Thiamylal.Approved, Vet Approved
ThiazinamThiazinam may increase the hypotensive activities of Nebivolol.Experimental
ThiethylperazineThiethylperazine may increase the hypotensive activities of Nebivolol.Withdrawn
ThiopentalThe serum concentration of Nebivolol can be decreased when it is combined with Thiopental.Approved, Vet Approved
ThioproperazineThioproperazine may increase the hypotensive activities of Nebivolol.Approved
ThioridazineThe serum concentration of Nebivolol can be increased when it is combined with Thioridazine.Approved, Withdrawn
Tiaprofenic acidTiaprofenic acid may decrease the antihypertensive activities of Nebivolol.Approved
TiboloneNebivolol may increase the hypotensive activities of Tibolone.Approved, Investigational
TiclopidineThe serum concentration of Nebivolol can be increased when it is combined with Ticlopidine.Approved
TicrynafenTicrynafen may increase the hypotensive activities of Nebivolol.Withdrawn
TimololTimolol may increase the hypotensive activities of Nebivolol.Approved
TinoridineTinoridine may decrease the antihypertensive activities of Nebivolol.Investigational
TipranavirThe serum concentration of Nebivolol can be increased when it is combined with Tipranavir.Approved, Investigational
TizanidineTizanidine may increase the atrioventricular blocking (AV block) activities of Nebivolol.Approved, Investigational
TofacitinibTofacitinib may increase the bradycardic activities of Nebivolol.Approved, Investigational
TolazamideNebivolol may increase the hypoglycemic activities of Tolazamide.Approved, Investigational
TolazolineTolazoline may increase the hypotensive activities of Nebivolol.Approved, Vet Approved
TolbutamideNebivolol may increase the hypoglycemic activities of Tolbutamide.Approved, Investigational
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Nebivolol.Approved, Withdrawn
Tolfenamic AcidTolfenamic Acid may decrease the antihypertensive activities of Nebivolol.Approved, Investigational
TolmetinTolmetin may decrease the antihypertensive activities of Nebivolol.Approved
TolonidineNebivolol may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypotensive activities of Nebivolol.Approved
TorasemideTorasemide may increase the hypotensive activities of Nebivolol.Approved
TrandolaprilTrandolapril may increase the hypotensive activities of Nebivolol.Approved
TranilastTranilast may decrease the antihypertensive activities of Nebivolol.Approved, Investigational
TranylcypromineThe serum concentration of Nebivolol can be increased when it is combined with Tranylcypromine.Approved, Investigational
TravoprostTravoprost may increase the hypotensive activities of Nebivolol.Approved
TreprostinilTreprostinil may increase the hypotensive activities of Nebivolol.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Tretinoin is combined with Nebivolol.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Nebivolol.Approved
TribenosideTribenoside may decrease the antihypertensive activities of Nebivolol.Experimental
TrichlorfonTrichlorfon may increase the bradycardic activities of Nebivolol.Vet Approved
TrichlormethiazideTrichlormethiazide may increase the hypotensive activities of Nebivolol.Approved, Vet Approved
TrifluoperazineTrifluoperazine may increase the hypotensive activities of Nebivolol.Approved, Investigational
TriflupromazineTriflupromazine may increase the hypotensive activities of Nebivolol.Approved, Vet Approved
TrimazosinNebivolol may increase the orthostatic hypotensive activities of Trimazosin.Experimental
TrimethaphanTrimethaphan may increase the hypotensive activities of Nebivolol.Approved, Investigational
TriptolideTriptolide may decrease the antihypertensive activities of Nebivolol.Investigational
TubocurarineTubocurarine may increase the bradycardic activities of Nebivolol.Approved
UdenafilUdenafil may increase the antihypertensive activities of Nebivolol.Approved, Investigational
UnoprostoneNebivolol may increase the hypotensive activities of Unoprostone.Approved, Investigational
UrapidilNebivolol may increase the orthostatic hypotensive activities of Urapidil.Investigational
ValdecoxibValdecoxib may decrease the antihypertensive activities of Nebivolol.Approved, Investigational, Withdrawn
ValsartanValsartan may increase the hypotensive activities of Nebivolol.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Nebivolol.Approved
VareniclineThe risk or severity of adverse effects can be increased when Nebivolol is combined with Varenicline.Approved, Investigational
VenlafaxineThe serum concentration of Nebivolol can be increased when it is combined with Venlafaxine.Approved
VerapamilVerapamil may increase the hypotensive activities of Nebivolol.Approved
VilanterolNebivolol may decrease the bronchodilatory activities of Vilanterol.Approved
VincamineNebivolol may increase the hypotensive activities of Vincamine.Experimental
VinpocetineNebivolol may increase the hypotensive activities of Vinpocetine.Investigational
XipamideNebivolol may increase the hypotensive activities of Xipamide.Experimental
XylazineXylazine may increase the atrioventricular blocking (AV block) activities of Nebivolol.Vet Approved
XylometazolineXylometazoline may increase the atrioventricular blocking (AV block) activities of Nebivolol.Approved, Investigational
YohimbineYohimbine may decrease the antihypertensive activities of Nebivolol.Approved, Investigational, Vet Approved
ZaltoprofenZaltoprofen may decrease the antihypertensive activities of Nebivolol.Approved, Investigational
ZileutonZileuton may decrease the antihypertensive activities of Nebivolol.Approved, Investigational, Withdrawn
ZimelidineThe serum concentration of Nebivolol can be increased when it is combined with Zimelidine.Withdrawn
ZiprasidoneThe serum concentration of Nebivolol can be increased when it is combined with Ziprasidone.Approved
ZofenoprilNebivolol may increase the hypotensive activities of Zofenopril.Experimental
ZomepiracZomepirac may decrease the antihypertensive activities of Nebivolol.Withdrawn
Food Interactions
Not Available

References

Synthesis Reference

Thomas Bader, Alfred Stutz, Harald Hofmeier, Hans-Ulrich Bichsel, "Process for preparation of racemic Nebivolol." U.S. Patent US20070149612, issued June 28, 2007.

US20070149612
General References
  1. Gielen W, Cleophas TJ, Agrawal R: Nebivolol: a review of its clinical and pharmacological characteristics. Int J Clin Pharmacol Ther. 2006 Aug;44(8):344-57. [PubMed:16961165]
External Links
Human Metabolome Database
HMDB0015594
KEGG Drug
D05127
PubChem Compound
71301
PubChem Substance
99443225
ChemSpider
64421
BindingDB
84735
ChEBI
64019
ChEMBL
CHEMBL434394
Therapeutic Targets Database
DAP000942
PharmGKB
PA151958426
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Nebivolol
ATC Codes
C07FB12 — Nebivolol and other antihypertensivesC07AB12 — NebivololC07BB12 — Nebivolol and thiazides
AHFS Codes
  • 24:24.00 — Beta-adrenergic Blocking Agents
MSDS
Download (69.1 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0Active Not RecruitingBasic ScienceBone, Age-related / Osteoporosis, Age-Related1
0CompletedTreatmentCardiac Steatosis and Lipotoxicity1
1CompletedTreatmentHigh Blood Pressure (Hypertension)2
2CompletedTreatmentHigh Blood Pressure (Hypertension)2
2CompletedTreatmentHypertension,Essential1
2, 3CompletedPreventionDiabetes Mellitus (DM) / High Blood Pressure (Hypertension)1
2, 3WithdrawnHealth Services ResearchHigh Blood Pressure (Hypertension)1
3Active Not RecruitingPreventionDuchenne's Muscular Dystrophy (DMD) / Heart Failure, Unspecified / Prophylaxis of cardiomyopathy1
3CompletedTreatmentHigh Blood Pressure (Hypertension)9
3CompletedTreatmentHigh Blood Pressure (Hypertension) / Peripheral Artery Disease (PAD)1
3CompletedTreatmentPrimary Arterial Hypertension1
3CompletedTreatmentStage 1 Hypertension / Stage 2 Hypertension1
3Unknown StatusTreatmentMarfan Syndrome1
4CompletedBasic ScienceMetabolic Syndromes1
4CompletedDiagnosticHigh Blood Pressure (Hypertension)2
4CompletedOtherHigh Blood Pressure (Hypertension) / Prehypertension2
4CompletedPreventionBlood Pressures / Hypertension Complicated / Left Ventricular Hypertrophy1
4CompletedSupportive CareHigh Blood Pressure (Hypertension)1
4CompletedTreatmentAltitude / Arterial hypoxia / Heart Failure, Unspecified1
4CompletedTreatmentAtherosclerosis / Endothelial Function1
4CompletedTreatmentChronic Heart Failure (CHF)1
4CompletedTreatmentCoronary Artery Disease / High Blood Pressure (Hypertension)1
4CompletedTreatmentHigh Blood Pressure (Hypertension)13
4CompletedTreatmentHigh Blood Pressure (Hypertension) / Left Ventricular Diastolic Dysfunction1
4CompletedTreatmentHigh Blood Pressure (Hypertension) / Pre-Hypertension1
4CompletedTreatmentHigh Blood Pressure (Hypertension) / Type 2 Diabetes Mellitus1
4CompletedTreatmentMicrovascular Angina1
4CompletedTreatmentStage 2 Diastolic Hypertension1
4RecruitingTreatmentDiastolic Heart Failure / Heart Failure With Preserved Ejection Fraction (HFpEF) / Pulmonary Hypertension (PH)1
4TerminatedTreatmentCoronary Artery Disease1
4TerminatedTreatmentHigh Blood Pressure (Hypertension)2
4Unknown StatusTreatmentEndothelial Dysfunction / High Blood Pressure (Hypertension) / Obstructive Sleep Apnea (OSA)1
4Unknown StatusTreatmentErectile Dysfunction (ED)1
4Unknown StatusTreatmentHigh Blood Pressure (Hypertension)1
Not AvailableCompletedNot AvailableHeart Failure, Unspecified / High Blood Pressure (Hypertension)1
Not AvailableCompletedNot AvailableHigh Blood Pressure (Hypertension) / Multiple System Atrophy (MSA) / Progressive autonomic failure1
Not AvailableCompletedDiagnosticArterial Hypertension1
Not AvailableCompletedDiagnosticHigh Blood Pressure (Hypertension)1
Not AvailableCompletedTreatmentHigh Blood Pressure (Hypertension)2
Not AvailableRecruitingTreatmentHeart Failure, Unspecified1
Not AvailableTerminatedTreatmentHigh Blood Pressure (Hypertension)1
Not AvailableTerminatedTreatmentHigh Blood Pressure (Hypertension) / Transplant; Failure, Kidney1
Not AvailableUnknown StatusNot AvailableHeart Failure, Unspecified1
Not AvailableUnknown StatusNot AvailableHigh Blood Pressure (Hypertension)1
Not AvailableUnknown StatusTreatmentFemale Sexual Dysfunction (FSD) / High Blood Pressure (Hypertension)1
Not AvailableWithdrawnTreatmentCentral Aortic Pressure1
Not AvailableWithdrawnTreatmentHigh Blood Pressure (Hypertension)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
  • Forest Laboratories Inc.
  • Forest Pharmaceuticals
  • Mylan
  • Physicians Total Care Inc.
Dosage forms
FormRouteStrength
TabletOral10.0 mg
TabletOral2.5 mg
TabletOral20.0 mg
TabletOral5.0 mg
Tablet, film coatedOral
TabletOral10 mg/1
TabletOral2.5 mg/1
TabletOral20 mg/1
TabletOral5 mg/1
Prices
Unit descriptionCostUnit
Bystolic 10 mg tablet2.09USD tablet
Bystolic 20 mg tablet2.09USD tablet
Bystolic 2.5 mg tablet2.06USD tablet
Bystolic 5 mg tablet2.06USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5759580No1995-06-022015-06-02Us
US6545040No2001-12-172021-12-17Us
US7803838No2006-08-292026-08-29Us
US7838552No2007-10-042027-10-04Us

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0403 mg/mLALOGPS
logP2.44ALOGPS
logP3.21ChemAxon
logS-4ALOGPS
pKa (Strongest Acidic)13.52ChemAxon
pKa (Strongest Basic)8.9ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area70.95 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity103.32 m3·mol-1ChemAxon
Polarizability41.98 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.8483
Blood Brain Barrier+0.7802
Caco-2 permeable-0.5549
P-glycoprotein substrateSubstrate0.7928
P-glycoprotein inhibitor INon-inhibitor0.7443
P-glycoprotein inhibitor IINon-inhibitor0.567
Renal organic cation transporterNon-inhibitor0.8016
CYP450 2C9 substrateNon-substrate0.8738
CYP450 2D6 substrateNon-substrate0.7248
CYP450 3A4 substrateNon-substrate0.6822
CYP450 1A2 substrateInhibitor0.5145
CYP450 2C9 inhibitorNon-inhibitor0.7876
CYP450 2D6 inhibitorNon-inhibitor0.5994
CYP450 2C19 inhibitorNon-inhibitor0.5923
CYP450 3A4 inhibitorNon-inhibitor0.9441
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8336
Ames testNon AMES toxic0.7132
CarcinogenicityNon-carcinogens0.9402
BiodegradationNot ready biodegradable0.9953
Rat acute toxicity2.7228 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.5769
hERG inhibition (predictor II)Inhibitor0.8381
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as 1-benzopyrans. These are organic aromatic compounds that 1-benzopyran, a bicyclic compound made up of a benzene ring fused to a pyran, so that the oxygen atom is at the 1-position.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Benzopyrans
Sub Class
1-benzopyrans
Direct Parent
1-benzopyrans
Alternative Parents
Aralkylamines / Alkyl aryl ethers / Benzenoids / Aryl fluorides / Secondary alcohols / 1,2-aminoalcohols / Oxacyclic compounds / Dialkylamines / Organopnictogen compounds / Organofluorides
show 1 more
Substituents
1-benzopyran / Alkyl aryl ether / Aralkylamine / Aryl fluoride / Aryl halide / Benzenoid / 1,2-aminoalcohol / Secondary alcohol / Oxacycle / Secondary amine
show 13 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
organofluorine compound, secondary alcohol, secondary amino compound, diol, chromanes (CHEBI:64019)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Receptor signaling protein activity
Specific Function
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately e...
Gene Name
ADRB1
Uniprot ID
P08588
Uniprot Name
Beta-1 adrenergic receptor
Molecular Weight
51322.1 Da
References
  1. Gielen W, Cleophas TJ, Agrawal R: Nebivolol: a review of its clinical and pharmacological characteristics. Int J Clin Pharmacol Ther. 2006 Aug;44(8):344-57. [PubMed:16961165]
  2. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  3. de Boer RA, Voors AA, van Veldhuisen DJ: Nebivolol: third-generation beta-blockade. Expert Opin Pharmacother. 2007 Jul;8(10):1539-50. [PubMed:17661735]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Protein homodimerization activity
Specific Function
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. The beta-2-adrenergic receptor binds epinephrine with an approximately ...
Gene Name
ADRB2
Uniprot ID
P07550
Uniprot Name
Beta-2 adrenergic receptor
Molecular Weight
46458.32 Da
References
  1. Nuttall SL, Routledge HC, Kendall MJ: A comparison of the beta1-selectivity of three beta1-selective beta-blockers. J Clin Pharm Ther. 2003 Jun;28(3):179-86. [PubMed:12795776]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]

Drug created on October 19, 2007 15:00 / Updated on April 23, 2018 23:09